Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - Citizens has reiterated its Market Outperform rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ:INO), maintaining confidence in the company’s DNA immunotherapy candidate. The target represents significant upside from the current price of $2.50, aligning with the broader analyst consensus of "Buy" according to InvestingPro data.
Inovio announced it has completed the rolling Biologics License Application (BLA) submission for INO-3107, its treatment for recurrent respiratory papillomatosis (RRP). The company expects the application to be accepted by year-end. Investors should note that Inovio is scheduled to report earnings in just 3 days, on November 7.
Citizens anticipates a Priority Review and full approval for INO-3107, comparing the likely regulatory pathway to Precigen’s experience with Papzimeos for the same indication. The firm projects a target PDUFA approval date to be announced within 60 days.
The price target is based on a risk-adjusted, discounted cash flow (DCF) analysis, according to Citizens’ research note.
Citizens will be hosting virtual meetings with Inovio’s management in New York City on December 1 and December 10, offering investors opportunities to engage with the company’s leadership.For deeper insights into Inovio’s financial health and growth prospects, InvestingPro offers a comprehensive Pro Research Report with 10+ additional ProTips and metrics that matter for biotech investors.
In other recent news, Inovio Pharmaceuticals has completed the rolling submission of its Biologics License Application (BLA) for INO-3107, a DNA immunotherapy candidate for treating recurrent respiratory papillomatosis (RRP) in adults. The company has requested priority review under the FDA’s Accelerated Approval program, which could lead to a decision by mid-2026. In the financial realm, Inovio reported a significant reduction in losses for the second quarter of 2025, with operating expenses down by 31% and net loss per share nearly halved. Oppenheimer has reiterated an Outperform rating with a $13.00 price target on Inovio, despite the FDA’s recent approval of a competing therapy, Precigen’s Papzimeos, for RRP. Jefferies, however, has lowered its price target for Inovio to $1.80 from $2.00, while maintaining a Buy rating. Meanwhile, JMP Securities continues to rate Inovio as Market Outperform, with a price target of $12.00, noting that the company is on track with its BLA submission timeline. These developments reflect Inovio’s strategic focus on advancing its ’3107 product and managing operational costs effectively.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.